ALNY - Alnylam upgraded to buy/outperform at Goldman Sachs RBC; shares up 7%

Shares of Alnylam Pharmaceuticals (ALNY +7.0%) are up in trading today following upgrades from Goldman Sachs and RBC Capital Markets. Goldman upgraded the stock to buy from neutral and set a $273 price target (~51% upside). RBC upgraded to outperform with a $225 price target (~24% upside). Goldman analyst Salveen Richter cites multiple drivers for the company beginning next year, including phase 3 data on Onpattro (patisiran) ATTR-cardiomyopathy. He adds that the phase 2 hypertension candidate zilebesiran is an underappreciated revenue driver. RBC's Luca Issi says that the stock is trading an attractive entry point at a 15% discount over October highs and ahead of catalysts, including the Onpattro data and the FDA action date for Leqvio (inclisiran) for hypercholesterolemia on Jan. 1, 2022. Needham analyst Joseph Stringer maintained his buy rating and raised his price target from $180 to $205 (~13% upside). Alnylam garnered attention last week after a

For further details see:

Alnylam upgraded to buy/outperform at Goldman Sachs, RBC; shares up 7%